|
|
Article: Rigel Initiates Multi-Dose Safety Trial of R112 for Allergic Rhinitis; Trial Designed to Establish Safety of R112 for Longer-Term Use.
- Article from:
- PR Newswire
- Article date:
- September 10, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Rigel Pharmaceuticals, Inc. today announced that it has initiated a multi-dose safety trial of R112, an experimental drug to treat allergic rhinitis. The goal of this trial is to establish the longer-term, multi-dose safety of R112 in various dosing regimens. Results of this trial are expected by January 2004 and will allow Rigel to enter into broader, longer-term, multi-dose efficacy trials in the first half of 2004.
In late July, Rigel released the results of a Phase I/II study which evaluated the efficacy and safety of a single intra-nasal administration of R112 in volunteers with asymptomatic seasonal allergic rhinitis. The study demonstrated significant ...